Anonym (Moa) skrev 2021-09-18 20:14:03 följande:
Om detta är din anledning till att tycka att allt som FHM skriver är citat 'råd' som inte intresserar dig så är det väldigt många länders 'råd' du helt avfärdar.
Följande är från mars 2021. British Columbia. Så tidigt som mars ändrade inte FHM på intervallet mellan doserna. Det kom senare. Men du ser i texten nedan att andra ändrade intervallet och varför.
bcmj.org/sites/default/files/BCMJ_Vol63_No2-complete.pdf
"BC?s public health officials have proposed a delay between the primary vaccination and booster to 35 days from the recommended 21
...
While new data may arise in the future that will challenge these conclusions, based on our analysis of currently available data, we support British Columbia?s decision to extend the dosing interval of Pfizer-BioNTech and Moderna vaccines from 21/28 days to 35 days for the following reasons:
There are inadequate vaccine supplies to maintain the maximum rate of primary vaccinations while adhering to strict approved dosing schedules for those who have already received the first dose. Partial immunity is granted after the first vaccine dose, as demonstrated in clinical trials. Organization In favor of extending dosing interval In favor of maintaining dosing as recommended by manufacturer Pfizer-BioNTech2 ?The safety and efficacy of the vaccine has not been evaluated on different dosing schedules as the majority of trial participants received the second dose within the window specified in the study design
There is no data to demonstrate that protection after the first dose is sustained after 21 days.? British Society of Immunology10 ??delaying a second ?booster? dose of a protein antigen vaccine (such as the two approved COVID-19 vaccines [Pfizer-BioNTech and AZN]) by 8 weeks would be unlikely to have a negative effect on the overall immune response post-boost.?
US FDA15 ?The second dose should be administered as close to the recommended interval as possible,? i.e., 21 days and 28 days respectively.
WHO13 ??the interval between doses may be extended up to 42 days (6 weeks), on the basis of currently available clinical trial data.?
European Medicines Agency9 ??the maximum interval of 42 days between the first and the second dose of the Pfizer-BioNtech vaccine should be respected to obtain full protection.?
US CDC14 ?There is no maximum interval between the first and second doses for either vaccine.
Therefore, if the second dose is administered >3 weeks after the first Pfizer-BioNTech vaccine dose or >1 month after the first Moderna vaccine dose, there is no need to restart the series.?
Government of Canada16 Pfizer-BioNTech minimum interval?19 days, authorized interval? 21 days, alternate interval?28 days Moderna minimum interval?21 days, authorized interval?28 days, alternate interval?none
Government of Quebec18 ?Les experts ont devoilé que la deuxième dose du vaccin soit administrée entre 42 et 90 jours après la première dose? Experts have recommended that the second dose of the vaccine be administered between 42-90 days after the first dose.
Government of Ontario19 Extend doses up to 42 days for some recipients of Pfizer-BioNtech.
Long-term care residents, high-risk retirement home residents and their essential caregivers, and concurrently vaccinated staff: second dose of Pfizer-BioNtech vaccine in 21 to 27 days. · All other recipients of the Pfizer-BioNtech vaccine: second dose 21 - 42 days · Moderna vaccine: 28 days Government of Alberta20 Second doses of COVID-19 vaccine will be offered within 42 days of the first dose Government of British Columbia17 Extend second dose to 35 days. ?A 35-day interval aligns with the operational reality that vaccine supplies will be back-end loaded with more vaccine scheduled to arrive in February and March 2021 than in December 2020 and January 2021 so everyone vaccinated will receive their second dose as scheduled in the coming weeks.? Table. Dosing interval recommendations for mRNA COVID-19 vaccines from a variety of international and Canadian jurisdictions. Tauh T, Mozel M, Meyler P, Lee SM Clinical 70 BC Medical Journal vol. 63 no. 2 | march 2021 Clinical
Immunity does not appear to wane for the duration studied (up to 42 days).
There is no obvious biological basis to believe that the long-term efficacy of the booster dose will be negatively affected by a short delay in receiving it. In an ideal world, there would be ample vaccine and adequate logistical machinery to mass vaccinate the entire population using approved, clinical-trial tested dosing intervals. Unfortunately, jurisdictions around the globe are facing shortages that require us to face the inequities of vaccine distribution, balance the ethical principles of beneficence, non-maleficence, and justice.
While there are no large clinical trial published data to guide prolonged delays of the second dose, there are data to suggest that delaying the second dose likely preserves the long-term boost in immunity without an unacceptable decrease in immunity in the intervening period between doses. Therefore, delaying the second dose, which allows for wider primary vaccination (and therefore a faster route to immunizing the most vulnerable members of our population), seems a reasonable option in situations of vaccine shortage, such as what we are currently facing in BC, throughout Canada, and around the world."
Jag ser de ändrade intervallet for att de inte hade tillräckligt många doser, for att befrämja populationen på bekostnad av individen, individuell immunitet sjonk men ansågs ändå acceptabel just for att främja populationen; "
without an unacceptable decrease in immunity in the intervening period between doses".
